Crossmark

ASO Visual Abstract: An Open-Label, Randomized Study of Melphalan/Hepatic Delivery System versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma

Crossref DOI link: https://doi.org/10.1245/s10434-025-17726-7

Published Online: 2025-07-15

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zager, Jonathan S. https://orcid.org/0000-0002-6886-4468
John, Johnny
License Information

Text and Data Mining valid from 2025-07-15

Version of Record valid from 2025-07-15
More Information

Article History

First Online: 15 July 2025

Disclosure

: J.Z. reports being global principal investigator in the FOCUS phase 3 study and serving on Delcath Systems Medical Advisory Board, as well as receiving education and training grant through Delcath. J.J. is an employee of Delcath Systems.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below